Spotlight: COVID-19 Special REPORT 2019/20 including more than 350 company profi les managed by

accelerating biomedical innovation BioM – central point of contact for pharma and biotechnology in Munich and Bavaria ❚ consulting for founders-to-be, start-ups & SMEs ❚ grant & seed fi nancing support ❚ pre-seed incubation & m4 award ❚ matchmaking, networking & partnering ❚ events, conferences & training ❚ representing Bavarian biotechnology world-wide ❚ investment opportunities ❚ central online platform: and much more job exchange, company database www.bio-m.org

CONTENT Greeting Bavarian Ministry of Economic Affairs Preface – Corona – The Hour of Truth for the Biotech Industry Prof. Horst Domdey – Spokesman Bavarian Biotechnology Cluster Company Development Strong Growth in Employment Bavarian Biotechnology in the Fight against COVID-19 Bavaria‘s Efforts in Dealing with the Coronavirus Pandemic COVID-19 Company Survey Challenges and Opportunities – a Snapshot of the Bavarian Cluster About this Study: For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/ or manufactures products on the basis of state-of-the-art molecular biological methods. The biotechnology companies were classified according to the location of the headquarter as ‘international’ or ‘native Bavarian’. The classification into OECD and non- OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem. Part of the data were collected in cooperation with Bio- Deutschland e.V. It was possible to achieve a response rate to the survey of more than 50% in the core group. Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2019. There are about 350 company profiles listed in the appendix of this brochure (pp. 41). Not every company listed is also considered in facts and figures in this survey, for example some companies with very specific services, or selected medical engineering companies. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in appendix. Also more than 500 Bavarian companies in medical engineering are not included in this survey (by numbers or with profiles). Professional Translation A Guest Contribution from Dr. Siegfried Bialojan Start-ups for the Medicine of the Future Tailor-made Programs for Bavarian Founders DigiMed Bayern For the Medicine of the Future International Affairs German-Japanese Cooperation for global Innovation Scientific Excellence in Biomedicine in Bavaria Focus on Cellular Therapy Innovation Centers in Bavaria Regional Networks in Life Sciences Published in July, 2020 Company Profiles 5 7 8 16 20 22 24 28 30 34 38 41 Biotech in Bavaria - Report 2018/19 3

Greeting Bavarian Ministry of Economic Affairs GREETING Bavarian Ministry of Economic Aff airs i W M S © t i W M S © t HUBERT AIWANGER Bavarian State Minister of Economic Affairs, Regional Development and Energy Deputy Prime Minister ROLAND WEIGERT State Secretary at the Bavarian State Ministry of Economic Affairs, Regional Development and Energy A current review of 2019 and the fi rst months of 2020 would not be complete without considering the current coronavirus pandemic. Cutbacks and changes affect not only the entire Bavarian economy and scientifi c institutions, but also all areas of public life and thus every individual in our society. The medium and long-term economic consequences for the industry are at present still diffi cult to predict, and the Bavarian biotechnology sector will certainly not be spared, too. We have indeed heard that many companies have already suffered a dramatic drop in revenues. Staying afl oat and maintaining supply chains is proving to be a huge challenge. With its emergency fi nancial aid program, the Bavarian State Government is doing its best to help employers, employees and businesses to weather the storm and to be ideally prepared for making a new start. At the same time, we are delighted at the speed and dynamism with which the Bavarian biotechnology sector has already responded to the challenge. Diagnostic companies and device developers have been very quick to adapt, further develop, and deliver their products. Various biotech and pharmaceutical companies are currently developing new therapeutic and vaccine candidates. CROs are supporting an increasing number of clinical trials on COVID-19 which are being conducted in Germany and Bavaria. Some Bavarian companies have delivered highly specifi c antibody tests at impressive speed. Network organizations, in particular, have an important role to play in this crisis by handling projects in clusters and interlinking research projects. Even if only a fraction of companies ultimately emerge stronger from the crisis, e.g., with revenue gains, the Bavarian biotechnology sector has reacted quickly and has been a great help right from the beginning of the present coronavirus crisis. We are in no doubt that the interplay of outstanding scientifi c institutions and dynamic entrepreneurial spirit offers enormous potential, which we as the State Government shall continue to support and promote. We aim to strengthen the global competitiveness of our attractive locations all over Bavaria. Eventually we hope that we can soon welcome international visitors again and look forward to showing them what Bavaria and its excellent biotechnology sector have to offer. Hubert Aiwanger Roland Weigert Roland Weigert Biotech in Bavaria - Report 2019/20 5

Preface Prof. Horst Domdey CORONA – THE HOUR OF TRUTH FOR THE BIOTECH INDUSTRY i M o B © PROF. HORST DOMDEY CEO of BioM; Spokesman Bavarian Biotechnology Cluster Dear reader, despite the huge opportunity for pharma and biotech companies to become the most important and therefore absolutely crucial players to fi nd a safe way out of the current pandemic, the Bavarian biotech industry has nonetheless been strongly hit by the unprecedented developments of the past months. While a small number of companies have indeed been able to take up the challenge of developing innovative diagnostics, therapies and vaccines to combat the ongoing spread of the coronavirus, the majority of the biotech industry has been strongly affected – just like all other industries – and is still fi ghting a hard battle to survive in the current diffi cult situation. This is the not all too astonishing result of a recent survey which was carried out by BioM. The pandemic has, as we all know, brought immense suffering to our society, the percentage of deaths among infected people, especially in countries with a less well-developed health-care system, has made us shudder. The economic consequences of the world-wide shut-downs of most of the industries and also of most of the academic institutions with their research labs has struck the biotech industry more or less completely unprepared. Fortunately, the political decision makers in Germany and Bavaria have made a lot of wise and mostly correct decisions. On the other hand, they have not (yet) fully recognized where the rescue out of the pandemic can come from, where it has to come from, namely from the pharma and biotech industries. What needs to be done is to put these two industries - along with our excellent health care system - at the forefront of the battle against COVID-19. Still, I believe that this can and will be the hour of truth for the international and also local biotech companies, because they now have the unique opportunity to prove their real signifi cance in situations like this. The developers of fast and safe, fi rst-class diagnostic tools have already passed their test and they will further optimize, possibly even revolutionize, the existing repertoire in the coming months. And although we have to keep in mind that the development of antiviral vaccines is – in retrospect – not a genuine success story, we will nevertheless continue to hope that safe vaccines will be developed to protect us from a possibly fatal infection. Finally, the therapeutic treatment of infected people with not only repurposed but also newly developed innovative drugs might eventually turn out to become the most successful path to get out of the current devastating situation. Taking everything together it seems that we are currently experiencing not only one of the biggest crises but also one of the most crucial moments in the history of the modern biotech industry, in other words its moment of truth. Sincerely yours, Prof. Horst Domdey Biotech in Bavaria - Report 2019/20 7

Company Development THE BAVARIAN BIOPHARMA SECTOR Number of Companies 400 Companies 60 Pharma 244 Biotech 30 Suppliers 66 CROs + 14 new biotech foundations 185 Bavarian Biotech (SME) Therapeutics Diagnostics Technology Platforms Devices and Reagents Industrial Biotech Bioinformatics & Digital Health Other 40 26 39 27 22 23 8 59 International Biotech Biotech in Bavaria - Report 2019/20 9

Company Development THE BAVARIAN BIOPHARMA SECTOR Employment Employees in Biopharma Companies 35,000 Employees in Life Sciences Research 10,000 13,000 Pharma 16,000 Biotech 3,000 Suppliers 3,000 CROs +5% +12% 11,000 International Biotech 5,000 Bavarian Biotech (SME) Biotech in Bavaria - Report 2019/20 11

DRUG PIPELINE OF BAVARIAN BIOTECH SMEs Number of Projects by Phase and Indication Company Development 2424 22 33 22 11 28 1212 11 3 33 1 11 2929 33 1010 22 14 27 22 22 11 11 11 66 22 10 6 11 5 R&D Preclinical Phase I Phase II Phase III 31 60 44 58 30 Marketed Drugs (derived from SMEs) 11 69 4 14 98 Indications 12 26 Oncology Infectious Diseases Autoimmune Central Nervous System Cardiovascular other Biotech in Bavaria - Report 2019/20 13 . s y S o h p r o M i f o s e t a d d n a c g u r d l a c i n i l c - n o n t n e r e f f i d 0 8 n a h t e r o m e r a d e d u l c n i t o N . 0 2 0 2 l i r p A f o s A

Company Development Based at BioPark Regensburg, 2bind and its partners came first in the EU call for Eureka Eurostars. The consortium will thus receive funding for the next three years for its development of new cancer diagnostics, which should enable patients to receive improved and individualized therapy. 2bind is a service provider for analytical methods, having started with the distribution of NanoTemper instru- ments. Eisbach Bio was the winner of the BIO-Europe 2019 Startup Slam in Hamburg. Founded in 2019, Eisbach Bio is a spin-off of the Biomed- ical Center Munich of the LMU, developing novel drugs that target chromatin regulatory mechanisms essential to tumors. The alphaSEPT team from Garching (Technical University of Munich) impressed both the audience and the jury of the 2019 Innovation Prize of Germany’s BioRegions with their approach to immune engi- neering in sepsis therapy. This new concept for treating sepsis aims to balance the excessive immune reaction at the onset of sepsis while preserving immune competence thereafter. The Fraunhofer-Gesellschaft, headquartered in Munich, celebrated its 70th anniversary in 2019. It was founded in Munich in 1949 to drive the innovation capability of the local economy. Today, Fraun- hofer is Europe’s leading organization for applied research, currently numbering 74 institutes and 28,000 employees in Germany alone. h t l a e H o d e m i l C © “In light of the coronavirus pandemic, Climedo Health decided to offer its platform for clinical data capture free of charge to COVID-19-related projects this year. The company has already collaborated with a number of researchers, MedTech start-ups and German health authorities to support studies on the virus, the validation of potential new virus test kits, and tracking patient symptoms with eDiary solutions.” VERONIKA SCHWEIGHART COO, Climedo Health Biotech in Bavaria - Report 2019/20 15 MorphoSys and Incyte Corporation have entered into a collaboration and licensing agreement to further develop and globally com- mercialize MorphoSys’ proprietary anti-CD19 antibody MOR208. The agreement has resulted in MorphoSys receiving an upfront payment of USD 750 million plus potential milestone payments of up to USD 1.1 billion. Acquisitions At the beginning of 2019, the Japanese compa- ny Hitachi Chemical Co., Ltd. acquired apceth Biopharma, based in Ottobrunn/Munich, for the sum of EUR 75 million. Furthermore, apceth Biopharma became a commercial manufacturer in Europe for Zynteglo® (formerly LentiGlobin), a gene therapy from the US American com- pany bluebird bio which is approved for the treatment of transfusion-dependent beta-thal- assemia. Mainz-based BioNTech acquired the operation- al antibody production unit of MAB Discovery, in early 2019, thereby leveraging the Munich- based biotech company’s proprietary tech- nologies to generate therapeutic monoclonal antibodies. Company Highlights – and a Glimpse into Science Bavarian Nordic, a Danish-Bavarian enterprise with a workforce of 150 in Martinsried, has received FDA approval for its vaccine against smallpox and monkeypox in adults who are at high risk of developing either infection. The vaccine is the only approved non-replicating smallpox vaccine in the USA and the only approved vaccine against monkeypox world- wide. Bavaria´s oldest Biotech company, Mikrogen, celebrated its 30th anniversary at the end of May 2019. Founded as a spin-off of the Max von Pettenkofer Institute of the Ludwig-Maxi- milians-Universität München (LMU), Mikrogen develops, produces, and distributes test sys- tems based on recombinant antigens. Mikrogen has also launched tests for the detection of coronavirus infections (see page 16).

COVID-19 „The current COVID-19 crisis is not yet over such that we have to be prepared for a second wave. Extensive and fast testing has been universally recognized as the best strategy to contain the spread of the pandemic. For this GNA has a unique technology that can make a diff erence.” DR. FEDERICO BÜRSGENS CEO, GNA Biosolutions l s n o i t u o s o B A N G © i health sector. For example, the start-up Ebenbuild, a spin-off of the Technical University of Munich (TUM), has developed a digital twin of the lung. Improved mechanical ventilation of critically ill COVID-19 patients is facilitated by artifi cial intelligence in the analysis of lung imaging. BioM-COVID-19 Platform BioM’s call for projects also showed that there is great interest in sharing information, expertise, technologies and capacities within the scope of COVID-19 research projects. BioM has therefore launched the national BioM-COVID-19 platform for companies, research institutions and cli- nics. Almost 100 offers and requests have already been posted on the platform. Initial success is already evident: BioM used the COVID-19 plat- form, for example, to organize diffi cult-to-obtain samples from coron- avirus-infected patients for biotechnology companies working on new diagnostic detection systems. Various productive partnerships between industry and research institutions or academic groups have also been established through the platform. Academic Approaches Academic institutions in Bavaria are also involved, of course, in the fi ght against the coronavirus pandemic. To better understand the spread of the virus, the Munich Tropical Institute at the LMU University Hospital Munich, headed by Prof. Michael Hölscher, is coordinating the „Pros- pective COVID-19 Cohort Munich“ (KoCo19) project together with the Bavarian State Government. In the Munich area, the infection status of around 3,000 representatively selected households is being investigated at various time intervals. The study aims to determine the number of undetected cases of COVID-19 in individuals who have not been tested due to the absence or low level of symptoms. The university hospitals of Regensburg and Erlangen have also started a large antibody study in the district of Tirschenreuth, which had a comparatively high number of Biotech in Bavaria - Report 2019/20 17 chemistry for the purpose of modifying messen- ger RNA (mRNA), which can thus be used to also develop an mRNA vaccine against SARS-CoV-2. Baseclick was founded in 2008 as a spin-off of the Ludwig-Maximilians-Universität München (LMU). Another company working in this fi eld of vaccine research against SARS-CoV-2 which is very experienced in the development of vac- cines is Bavarian Nordic, based in Martinsried near Munich. Various biotechnology companies are working on highly innovative approaches, moreover, that directly target the novel coronavirus. One good example is Ethris, which develops mRNA-based drugs, the end products of which are antibodies produced by the recipient. Cfm Oskar Tropitzsch and Iris Biotech from Marktredwitz in northern Bavaria are working on a new antiviral agent against SARS-CoV-2, and are already in close contact with leading research institutes. In addi- tion, Cfm Oskar Tropitzsch has another product in the value-added chain of a large diagnostics company and supports the company in securing raw materials for its test kits. In May, Martins- ried-based Immunic Therapeutics, which focu- ses mainly on the development of therapies for the treatment of autoimmune diseases, announ- ced the start of a new clinical development pro- gram with its advanced drug candidate IMU-838 (a DHODH inhibitor), which has revealed antivi- ral activity against the RNA virus SARS-CoV-2 in cellular experiments. Bavaria is also well represented in the digital Dr. Lars Ullerich, CBO of GNA Biosolutions, explains Hubert Aiwanger (left), Bavarian State Minister of Eco- nomic Affairs, the rapid test for SARS-CoV-2 © StMWi/ Elke Neureuther

How concerned are you with the Consequences of the Coronavirus for your Company? COVID-19 5% 3% 40% 17% 35% 55% of the responding companies are concerned about the coronavirus pandemic extremly concerned very concerned relatively concerned not so concerned not concerned at all COVID-19 relevant Products/Services (Multiple answers were possible) Ventilators/other hardware 2% Protective equipment/disinfectants 1% Digital tools 2% Laboratory analytics Pivotal studies Vaccines development Diagnostics development Drug development 64% of the responding companies are involved in COVID-19 product development 10% 11% 20% 19% 23% No Other 6% 36% Sales Development Decline in sales existential 5% Decline in sales (up to 50%) Decline in sales (up to 20%) Decline in sales (up to 5%) Sales increase No changes 12% 15% 18% 13% 50% of the responding companies had declining sales 13% of the responding companies had increasing sales 37% Biotech in Bavaria - Report 2019/20 21

Guest Contribution established technology parks are available in many regional clusters, what they essentially offer is space in an inspiring science environ- ment and a range of coaching services. The full-service support of successful incubators in the US (e.g. BioLabs/LabCentral) is completely lacking in Germany. While it is by no means possible to replicate the US approach 1:1 in Germany, Track Record – in 2017 alone, 10% of early-phase venture capital in the US went to start-ups in or from this incubator – should Recent fi nancing rounds and partnerships have demonstrated that these considerations are not merely theoretical: professionally nurtured ideas and start-ups do indeed lead to more successful business development – signifi cant fi nancing rounds for start-ups supported directly by the investors mentioned above (BIVF, MPM, HTGF) are a solid testament to this fact: Munich has again been a pioneer here, with MPM being the fi rst to invest in IOmix. The latest examples stem from BIVF, which has been involved in 50% of its portfolio companies from the very beginning. help drive similar, professional entrepreneur- ial developments forward here in Germany too. The intentions in Heidelberg (BioLabs HD) in this respect are an important experiment. The translational support offered by investors has improved immensely: among these, nota- bly, the corporate venture funds (e.g. Boeh- ringer Ingelheim Venture Fund), certain other early-stage investors (good examples include MPM and Kurma in Munich), and HTGF have recognized the importance of profession- al company building and are very actively involved on a professional level during the early phase. In addition, more constructive activities are certainly taking place in the area of TTOs, as innovation enablers who actively support ideas with professional project management while also promoting project funds dedicated to company building. Thus, we can remain hopeful that a momentum has emerged here which will help to counteract the frequent excuse of the “risk-averse mindset” and ‘risk-averse capital’ with risk-reducing initiatives. Although the two criteria of “effectiveness and effi ciency” in trans- lating existing potentials in Germany are still conditional, we can be all the more hopeful that precisely because of the crisis the need to strive for more professional translation, as discussed above, must be given greater consideration and also be pursued long-term (after the crisis). About EY: EY is a globally connected, multidisciplinary pro- fessional services organization with headquarters in London, UK. The organization is one of the market leaders in auditing, tax consulting, trans- action consulting and management consulting. EY is present at 20 locations in Germany. Biotech in Bavaria - Report 2019/20 23

Start-ups for the Medicine of the Future m4 Award: Five calls – nine Spin-offs Since 2011, the Bavarian State Ministry of Eco- nomic Affairs, State Development and Energy has supported the m4 Award, which was ini- tiated by BioM. This pre-seed competition is aimed at Bavarian academic research projects with spin-off potential in the field of biomed- icine. With grant money of up to EUR 500,000 for two years, the competition supports the development and validation of the respective project with a view to creating a spin-off. The scientists receive not only financial support but also active support from BioM and other partners as well as industry experts. Out of five calls, a total of 23 research projects with m4 Award ceremony at Munich Residence - Prof. Horst Domdey presents the award winners. © BioM The five winner teams of the m4 Award 2019 with Dr. Ulrike Wolf (Department Head of the Bavarian State Ministry of Economic Affairs) and Prof. Horst Domdey (Managing Director, BioM). © BioM spin-off potential have been awarded. Nine promising start-ups have been founded so far, highlighting the success of the pre-seed award and importance of this initiative. PreOmics is one of the m4 Award success stories. In 2013, the team from the Max Planck Institute of Biochemistry in Martinsried won the m4 Award with its pre-seed project, leading to the foundation of PreOmics in 2016 by Dr. Nils A. Kulak and Dr. Garwin Pichler. The start-up develops and produces innovative technologies for pre-analysis of samples for mass spectrometry. PreOmics success- fully secured series A financing and is already selling its products while expanding sales globally. Two further recent successes show the innovative strength of Bavaria: Having achieved the m4 Award in 2019, the research team headed by Prof. Stephan Sieber, Technical University of Munich (TUM), received a special honor in mid-July: In recognition of their current efforts to combat antibiotic resistance, Sieber and his team were awarded the Merck Future Insight Prize 2020. The researchers aim to use the prize money of EUR 1 million to advance the devel- opment of new drugs against multi-resistant bacteria and bring them to market. Just recently, Tubulis, awarded 2017 with the m4 Award, announced the close of a EUR 10.7 million Series A financing round to accel- erate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with support from Seventure Partners, coparion, Bayern Kapital, and OCCIDENT alongside signif- icant contributions by high net worth individuals and the founders. Tubulis was spun out in 2019 from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin (FMP) and the Ludwig-Maximil- ians-Universität München (LMU) with the aim of expanding the ther- apeutic potential of ADCs for cancer and other disease indications. Biotech in Bavaria - Report 2019/20 25

accelerating medical innovation BioM inQlab we guide you from idea to success virtual incubator for the future of medicine Startup Coaching get hands-on support Mentor Circle inspired by experience Pitch Doctor how to convince investors BioEntrepreneur Bootcamp validate your business idea BioEntrepreneur Lounge join the community BioAngels find the right investor m4 Award create the future of medicine BioEntrepreneurship Summit connecting the ecosystem www.bio-m.org

the next medicine... Let’s develop it together. At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the gene to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome, at the time when you expect it. Our extensive track record includes the commercialization of pioneering therapies and manufacturing of a wide variety of drugs. We continuously invest to solve not just the current, but also the future challenges. Together, we can bring your next medicine to life. Visit pharma.lonza.com USA +1 201 316 9200 Japan +81 (0)3 6264 0600 Europe and rest of world +41 61 316 81 11 Email pharma@lonza.com © 2020 Lonza. All rights reserved.

International Affairs with many years of experience working with Japanese partners, interact- ing with other cultures is part of our everyday life. So far, we have not experienced any major intercultural hurdles. B: For us, the intercultural topic was bumpy at the beginning. Too often, self-announced German Japan-experts are describing the Japanese market as they see it. Unfortunately, this view is often biased – and worse even wrong. We gained significant speed, as we started to include Japanese-born experts sharing their thoughts on German behavior and on the most successful approach. This can still be biased, but here, the Japanese colleagues working for and at BioM really made a difference in explaining us local actors and their behavior. Still, the language remains quite a hurdle in general for further business development in Japan – for sure on both sides. BioM: What success do you hope to achieve by the end of the project and beyond? I: By combining Immunic’s expertise in targeting intracellular metabolism with the vast experience and resources of each of our partners, a Jap- anese pharma company, the University of Kyoto and quattro research GmbH, we are hopeful that the results will lead to the development of new therapeutic options for a range of underserved diseases. Addition- ally, we hope it will lead to the development of qualified biomarkers that enable us to identify patients who may best respond to such therapies. B: Bicoll aims to have a prototype ready, being able to make individual predictions possible for the best treatment options for patients, and iden- tifying the right compounds for it. BioM provides Bavarian companies with support in finding financing and cooperating partners and in developing interna- tional markets. Find more information here: www.bio-m.org/en/our-services/international-affairs Biotech in Bavaria - Report 2019/20 31 network, Bicoll has an accessible partner on the local campus in Martinsried, with whom the needs and demands for an ideal matching of collaboration partners could be discussed. That BioM employed a Japanese speaking project manager in the conception phase was the clue to success for the partner search in Japan, and helped with building trust later in the project on both sides. BioM: What expectations did you have of the BMBF-funded InnoMuNiCH program and how were they met? B: Our main expectation of getting valuable, risk minimizing support through a representative cluster organization having a reliable name in Japan, was fully met. Furthermore, having access to the local decision makers and – in a best-case scenario – introducing the project also on governmental level was of high importance. The missing points here, which are still not completely solved, are firstly, to persuade the Japanese government to set up a matching pro- gram to support the Japanese partners equally, and secondly, to receive further significant sup- port by the cluster, backed up financially by the BMBF, for the establishment of the achieved foothold, not only for Bicoll itself, but also for other companies in the region. I: Through the InnoMuNiCH project, Immunic set out to establish new collaborations with Japanese partners in order to expand on those we already had. As a result of our participation in this project, we have successfully built great relationships with two Japanese collaborators, a pharma company and the University of Kyoto, in addition to Munich, Germany-based quattro research GmbH. BioM: InnoMuNiCH links Germany with Japan, one of the world’s largest health care markets. Despite the common interests of advancing global healthcare, the cultures of the two coun- tries are significantly different. How well were you able to overcome intercultural hurdles? I: As a global biotech company with an already existing, close collaboration with Daiichi Sankyo prior to joining the InnoMuNiCH project, and

Cluster Excellence for Business Innovation and Growth in the Health Sector (CE4BIG) BioM is partner in a new European project, CE4BIG – Cluster Excellence for Business Innovation and Growth in the Health Sector. It was selected to receive funding under the EU COSME “European Cluster Excellence” initiative, which aims to foster cluster collaboration on a European-wide scale. The ultimate objective is to strengthen both, clusters and SMEs, to jointly master global competition and work on the answers to the challenges of personalized medicine. CE4BIG federates four European healthcare clusters, with similar regional smart specialization strategies supporting the development of advanced therapies for personalized medicine. In addition to BioM, the consortium consists of the project leader, Atlanpole Biotherapies from France, BioWin from Belgium, and Life Science Krakow from Poland. The project intends to promote business growth and to raise the innovation capacity of SMEs. Professional cluster services will be optimized through targeted activities including the ClusterXchange scheme, which enables and fosters cross-border collaboration between innovation stakeholders in the innovation ecosystems of the project partners. The exchanges aim at helping SMEs within the partnership, design and fine-tune their business models, develop new partnerships, seize new business opportunities abroad, and secure funding for business and innovation to reach proof of technology and grow beyond. The project will also benefit cluster management and strategic skills through customized training and transnational clus- ter-to-cluster missions. This will enable the consortium to exchange expertise in topics of common interest for SMEs, and to stimulate the dialogue between SME managers and business/innovation support stakeholders. The CE4BIG project started on February 2nd and will be funded for 24 months. Biotech in Bavaria - Report 2019/20 33

Competence Centers The T-cell receptor study into the treatment of multiple myeloma, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), for example, which was conceived by Medigene, a biotechnology company based in Martinsried near Munich, is led by Regensburg University Hospital. In addition to the scientists at Uni- versity Hospital Erlangen, University Hospital Würzburg and other university medical centers (Freiburg, Mainz, Heidelberg, Frankfurt, Dres- den) are also taking part in the study investigat- ing a modified approach of CAR T-cell therapy introducing a tumor recognizing receptor into patient´s T-cells. Erlangen The development and clinical testing of innova- tive immunological therapies are also the focus at the German Center for Immunotherapy at Friedrich Alexander Universität Erlangen-Nürn- berg. The production of cellular therapeutics is subject to stringent legal requirements and must comply with the guidelines for good manufac- turing practice (GMP). An appropriate ultraclean medical laboratory for manufacturing living cell products has been established at University Hospital Erlangen. Using dendritic cells, the lab develops and deploys CAR T-cell therapies, T-cell receptor-based therapies and tumor cell vaccines. Therapies based on antibodies (includ- ing immune checkpoint inhibitors), kinase inhib- itors, antisense oligonucleotides, or low molec- ular active ingredients, are also used. The focus lies on the testing of novel therapies in clinical trials and comparing them against conventional treatment concepts to evaluate the safety and efficacy of cell therapies. The clinical facility is therefore an excellent partner in an alliance of international study centers. This initial clinical trial began in spring 2019 at Medical Clinic 5 – Hematology and Inter- nal Oncology of University Hospital Erlangen, headed by Prof. Andreas Mackensen, who also coordinates this division at the new “Bavarian Cancer Research Center.” Bavarian Cancer Research Center – an Alliance of six University Hospitals Despite outstanding basic research, Bavaria also has its deficits in terms of patient-centered cancer research. It is largely conducted on a project-by-project basis, without any sustainable growth in terms of human resources and infrastructures. Excellence is not achieved across the board, but rather only in individual focus areas. Patients derive insufficient benefit from the results of basic research. The future of cancer medicine and research will only be viable based on an alliance of university hospitals at one well-structured center. A fundamental rethink is taking place here. The main idea behind the new Bavarian Cancer Research Center is to develop special expertise and the necessary infrastructures specifically at individual sites which can then be utilized by all sites. To this end, the Bavarian government launched a EUR 150 million funding program to establish an infra- structure alliance and furthermore to network infrastructures in cancer research and the provision of patient care. All six university hospital sites in Bavaria have been integrated; the focus lies in the genuine translation of research results to the benefit of patients. The first light- house projects are due to start in 2020. www.bzkf.de Würzburg Not only with CAR T, but also the more specific DAR T (standing for CD123 x CD3 dual affinity re-targeting - DAR T - bi-specific anti- body-based molecule), University Hospital Würzburg has demon- strated its prowess in immunotherapy – in both research and appli- cation. Researchers in Würzburg have gained special know-how in the handling and design of bispecific linker molecules, which are more effective at bringing the target cell (tumor) and effector cell(s) (T cells, including tumor killer cells) closer together. This expertise is the result of working for many years with the biTE technology devel- oped by Micromet, the Munich-based biotech company acquired by Amgen. Under the name Blincyto™, this linker molecule is the first novel form of application to have been granted marketing authoriza- tion. At the beginning of 2020, the multi-year phase I study currently being conducted at University Hospital Würzburg revealed very good results in patients with advanced multiple myeloma receiving thera- py with the new bispecific antibody AMG 420. Bispecific antibodies produced with BiTE technology can bind T cells to the myeloma cells, resulting in their destruction. The study was designed at the clinic headed by Prof. Hermann Einsele with lead investigator Prof. Max Topp; it is here where most of the participants have also been recruited. The bispecific principle works, in this case, as follows: The first target is the B-cell maturation antigen, BMCA, which is mainly found on myeloma cells. The second is CD3, a protein found on the surface of T cells. By binding to these two proteins, AMG 420 attracts and binds T cells to the cancer cells. The killer cells can thus destroy the myeloma cells which would otherwise protect them- selves from T-cell infiltration by means of biochemical camouflage. Biotech in Bavaria - Report 2019/20 35

BIOTECHNOLOGY | MEDICAL ENGINEERING | PHARMA | ANALYTICS | HEALTH THE SUCCESSFUL INNOVATION CENTRE MADE IN REGENSBURG Health Industry of Regensburg ➜ 1.8 billion Euro turnover ➜ 20.000 employees Cluster BioRegio Regensburg ➜ 55 companies (Life Sciences) ➜ 3.980 employees BioPark Regensburg ➜ 18.000 sqm area ➜ 38 companies, 608 employees. ➜ 64 start-ups since 1999 ➜ fl exible leasehold concept & single offi ces ➜ direct motorway connection ➜ located on the University Campus ➜ own day-care facility ➜ conference rooms and theatre A company of the City of Regensburg Member of Am BioPark 13 | D-93053 Regensburg | Phone: +49 941 92046-0 | Fax: -24 | info@biopark-regensburg.de | www.biopark-regensburg.de

Innovation Centers in Bavaria Erlangen and Nuremberg The European Metropolitan Region Nuremberg is an internationally leading location for medical technology. Cluster organization: Medical Valley Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm) www.medical-valley-emn.de Straubing The BioCampus in the port of Straubing focu- ses on creating value from biobased resour- ces, biomass logistics and start-up manage- ment. In close vicinity to the TUM Campus Straubing for sustainability and industrial biotechnology, it offers lab space, offi ces, start-up and business support. Cluster Orga- nization: BioCampus Straubing GmbH Incubator: BioCubator (1,200 sqm) www.hafen-straubing.de IZB Martinsried and Freising The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on life sciences) has developed into one of the top biotechno- logy centers in the world and offers young biotech start-ups 26,000 sqm of modern building infrastructure for biotechnology. www.izb-online.de Biotech in Bavaria - Report 2019/20 39

Company Profiles 41

abf diagnostics GmbH PHARMA SUPPLIER & TRADE abf diagnostics develops, manufactures and markets products and solu- tions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and decen- tralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces. Gewerbepark 14 D-85402 Kranzberg Phone: +49 (0) 8166 9986 130 E-Mail: info@abfdiagnostics.com Internet: www.abfdiagnostics.com Actarmo Medical GmbH CRO Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory Actarmo is a Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experiencend team we offer GMP laboratories as well as consultancy activities. adivo GmbH PHARMA ANIMAL HEALTH Keywords: Pain, Oncology, Inflammation, Antibody, Drug Development adivo is a German biotech company generating species-specific therapeutic antibodies for companion animals. The adivo team aims to initially address high medical needs in dogs including chronic inflammation and cancer, with the potential of expanding activities into the development of therapeutics for other species in the future. Using its fully canine-based antibody library, adivo, either alone or with partners, intends to generate therapeutics for dogs that are well tolerated and efficacious. advanceCOR GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation advanceCOR is a biotech company focusing on personalized medicine in cardiovascular diseases. Revacept, a biological drug (lesion specific inhibitor of atherothrombosis) has completed a phase II trial in patients with stroke and cerebral vascular syndromes. A phase II clinical trial for the treatment of coronary artery disease has completed patient recruitment. Further preclini- cal candidates are under development. advanceCOR is financed by MIG AG, KfW, Bayernkapital, HTGF, Occident and BioM AG. Robert-Koch-Allee 29 D-82131 Gauting Phone: + 49 (0) 89 614233 0 Internet: www.actarmo.com Am Klopferspitz 19 c/o IZB D-82152 Planegg-Martinsried Phone: +49 (0) 89 - 588 08 84 71 E-Mail: info@adivo.vet Internet: www.adivo.vet Fraunhoferstr. 9a D-82152 Martinsried Phone: +49 (0) 89 2000 204-10 E-Mail: info@advancecor.com Internet: www.advancecor.com 43 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Agrobiogen GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Agrobiotechnology, Bioanalytics, Laboratory Agrobiogen focuses on and is experienced in the application of molecular- genetic techniques in livestock animals (especially moleculargenetic diag- nostics). Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a ser- vice for breeders, veterinarians and companies. Larezhausen 3 D-86567 Hilgertshausen Phone: +49 (0) 8250 9279040 E-Mail: info@agrobiogen.de Internet: www.agrobiogen.de Agrolytix GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Agrolytix is your competent partner around the themes of microencapsula- tion and micronization. The company specializes in the areas of agrochemi- cals and cosmetics. We are happy to assist in the development and produc- tion of your new products or offer you our technologies as services. Alexion Pharma Germany GmbH PHARMA & CHEMICAL INDUSTRY Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world. Alexion operates a branch office in Germany to support patients locally. Further information about Alexion can be found at www.alexion.com or at www.alexion.de. ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Infectious Diseases, Oncology, Autoimmune Diseases Algora offers a broad range of services for phase II-IV clinical trials as well as for observational studies in Germany, with key competencies in study start-up, clinical monitoring, data management, and statistical analysis. Experienced in oncology and infectious diseases since the first days of the company in 1989, we later gained additional expertise in immunology and entered the field of nutritional studies while we continued to cultivate strong relations with the medical community. Cauerstr. 4 D-91058 Erlangen Phone: +49 (0) 9131 85-29452 E-Mail: info@agrolytix.com Internet: www.agrolytix.com Landsberger Straße 300 D-80687 München Phone: +49 (0) 89 45 70 91 300 Internet: www.alexion.de Münchner Str. 11 D-85540 Haar Phone: +49 (0) 89 613727-0 E-Mail: cro@algora.de Internet: www.algora.de 45 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR Founded 2002, AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on a real-time isothermal amplification technique in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazy- plex® system you identify pathogenic bacteria within 15 min, screen swabs for multi-resistant bacteria within 20 min or realise Meningitis diagnostics directly from CSF in 30 min. AMS Advanced Medical Services CRO Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service, Regulatory Affairs, Data Management, Pharmacovigilance AMS specialises in Global Drug Development, are market leaders in Health Economics and Public Health Benefit Assessments of pharmaceuticals, as well as HTAs and Relative Effectiveness Assessments for medical devices. AMS can provide market access programs in Europe and field force services in German speaking countries. The comprehensive suite of AMS services also include ePRO solutions, strategic consultancy and staff development training. AMSilk GmbH BIOTECH NEW MATERIALS AND COMPOUNDS Keywords: New Materials, Industrial Biotechnology Werkstr. 2 D-83555 Gars-Bahnhof Phone: +49 (0) 8073 91693-50 E-Mail: info@amplexdiagnostics.de Internet: www.eazyplex.com Rosa-Bavarese-Str. 5 D-80639 München Phone: +49 (0) 89 2000074-100 E-Mail: Medical.Science@ams-europe.com Internet: www.ams-europe.com AMSilk GmbH is the world’s first industrial supplier of synthetic silk bio- polymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers combine the advantages of natural products with the possibility of large scale, industrial production processes. AMSilk´s high-performance biopolymers are distributed in the form of Biosteel® fibers or as a coating solution for medical devices. Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 579 5393-0 E-Mail: info@amsilk.com Internet: www.amsilk.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 47

Astellas Pharma GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to changing tomorrow by improving the health of people around the world. We focus on oncology, anti-infectives, urology and transplantation as pri- oritized therapeutic areas while advancing new therapeutic areas and dis- covery research leveraging new technologies and modalities. The German headquarters are based in Munich. Located here are sales, marketing and medical. ASPHALION, S.L., Zweigniederlassung München CRO Keywords: Regulatory Affairs, Pharmacovigilance, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing ASPHALION is a Scientific and Regulatory Affairs consultancy firm with offic- es in Barcelona, Madrid, Munich and London. Founded in 2000, ASPHALION now consists of a team of over 100 professionals offering services to Pharma and Biotech companies in Drug Development, Regulatory Strategy, Medical and CMC Writing, Regulatory Submissions, eSubmission, Pharmacovigilance and Training. ASPHALION operates in a global environment with regulatory submission expertise mostly in EU and North America. ATRES engineering biogas BIOGAS Keywords: Bioprocessing, Agrobiotechnology Our top products for the top performance of your biogas plant! Stable biogas production, high effectiveness, high availability of the plant. Aurigon GmbH BIOTECH PRECLINICAL SERVICES Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service AURIGON is an independent CRO offering a full range of in vivo and in vitro non-clinical services. These services include, but are not limited to: PK/ PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing. We’re big enough to provide a full service, but small enough to fully adapt to your needs. AURIGON operates offices in Munich and state-of-the-art GLP- and GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Georg-Brauchle-Ring 64-66 D-80992 München Phone: +49 (0) 89 4544-1057 E-Mail: info@de.astellas.com Internet: www.astellas.de Leopoldstrasse 244 D-80807 München Phone: +49 (0) 89 208 039 280 E-Mail: munich@asphalion.com Internet: www.asphalion.com Hansjakobstr. 127a D-81825 München Phone: +49 (0) 89 45 21 60 8-0 E-Mail: lab@atres-group.com Internet: www.atres-group.com Planegger Str. 9a D-81241 München Phone: +49 (0) 89 780 720 010 E-Mail: info@aurigon.de Internet: www.aurigon.de 49

baseclick GmbH BIOTECH DEVICES & REAGENTS Keywords: PCR, Nanobiotechnology, Chip/Array Technology, Baseclick GmbH was founded in 2008 as a spin out of the LMU in Munich by Prof. Dr. Thomas Carell. Baseclick utilizes the “click chemistry”, discovered by the Nobel laureate Prof. Dr. Barry Sharpless, and developed a wide range of nucleic acid modification products, e.g. EdU proliferation kits, labeling of nucleotides and preparation kits for “Next Generation Sequencing” (NGS) and for the development of RNA-based drugs. baseclick GmbH out-licensed this technology to leading companies worldwide. Basilea Pharmaceutica Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The com- pany currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich. Bavarian Nordic GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox and monkeypox vaccines. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. BN was founded in 1994 and is headquartered in Denmark. The company has more than 500 employees in Europe and USA and is listed on the Copenhagen Stock Exchange. Baxter Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diver- sified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Floriansbogen 2-4 D-82061 Neuried Phone: +49 (0) 89 9699 3401 E-Mail: info@baseclick.eu Internet: www.baseclick.eu Elsenheimerstraße 7 D-80687 München Phone: +49 (0) 89 7857674-0 E-Mail: basilea.info@basilea.com Internet: www.basilea.com Fraunhoferstr. 13 D-82152 Martinsried Phone: +49 (0) 89 255446-030 E-mail: hho@bavarian-nordic.com Internet: www.bavarian-nordic.com Edisonstr. 4 D-85716 Unterschleißheim Phone: +49 (0) 89 31701-0 E-Mail: info_de@baxter.com Internet: www.baxter.de 51

betapharm Arzneimittel GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pain, Drug Development Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one oft the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m. Kobelweg 95 D-86153 Augsburg Phone: +49 (0) 821 74881-0 E-Mail: info@betapharm.de Internet: www.betapharm.de Bicoll GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Natural Compounds, Nutraceuticals, Medicinal Chemistry, Oncology, R&D Service, Agrobiotechnology, Small Molecules Bicoll is an expert in field of small molecules. It provides fastest and most successful method from initial screening to the animal tests (cycle time <9 months) and products. It provides the most favorable starting points for any innovation campaign to develop one of TOP-200 drugs. High tech plant-de- rived natural product chemistry is toped up by validated experience in medicinal chemistry. The robust technology serves biological and biochemi- cal high-throughput-screening approaches. Bind-X GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. Bind-X products are capable of solidifying almost any permeable material and providing additional functional properties. Foremost they always increase the sustainability of Bind-X clients in the worldwide mining, agriculture and construction industry. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 820106-30 E-Mail: contact@bicoll-group.com Internet: www.bicoll-group.com Am Klopferspitz 19 D-82152 Planegg-Martinsried Phone: +49 (0) 89 2620344-0 E-Mail: info@bind-x.com Internet: www.bind-x.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 53

Biogents AG BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology Biogents develops, produces & sells innovative trapping systems against mosquitoes & fl ies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand fl ies. These systems are already being used by leading health organizations (e.g. CDC, USA), several armed forces and other governmental bodies & public entities (incl. quarantine depart- ments, research institutes & universities). Biogents also offers a fee-for-ser- vice business for insect repellents and attractants. BioLink Informationstechnologie GmbH BIOTECH BIOINFORMATICS Keywords: Laboratory The BioLink GmbH, an information-technology company, was founded in 1997 to serve as High Security Internet Provider and as Software Developer for Laboratory-Informations-Management-Systems (LIMS). It was specifi cally the software-developing business which evolved over the last years. Based on the concept to design and develop personalized LIMS solutions, BioLink put forth a number of softwares aimed to support laboratory processing as well as certain aspects of genetic engineering. Biomax Informatics AG BIOTECH BIOINFORMATICS Keywords: Bioinformatics, Industrial Biotechnology, Data Management, Personalized Medicine, Agrobiotechnology, Informatics, Data Management and Biostatistics Biomax Informatics provides software solutions for knowledge management in the life science markets: AILANI is a semantic search platform that cata- lyzes digital change and accelerates the innovation cycle. NeuroXM is the one-stop-shop to decipher brain physiology. The Clinical Integration System ensures access to real world evidence data, which is critical to train Artifi cial Intelligence to support clinical decisions at the point of care. Biomax is certi- fi ed according to ISO 9001 and ISO 27001. Weißenburgstr. 22 D-93055 Regensburg Phone: +49 (0) 941 5699 6947 E-Mail: biogents@biogents.com Internet: www.biogents.com Lochhamer Straße 9 D-82152 Martinsried Phone: +49 (0) 89 741595-0 E-Mail: info@biolink.de Internet: www.biolink.de Robert-Koch-Str. 2 D-82152 Martinsried Phone: +49 (0) 89 895574-0 E-Mail: info@biomax.com Internet: www.biomax.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 55

Biontex Laboratories GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents Biontex Laboratories GmbH is an innovative biotech company with focus on transfection technology, covering the introduction of genetic material and proteins into eukaryotic cells by synthetically produced carrier systems. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects. Bio-Rad Laboratories GmbH BIOTECH DEVICES & REAGENTS Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service Bio-Rad was founded in 1952. The headquarter is in Hercules, California. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceuti- cal firms and classrooms around the world. Bio-Rad’s key competencies incl. separation, purification and analysis. The company is a leader in electropho- resis, protein assays, gel image analyis, quality controls, diabetes monitor- ing, autoimmune testing, blood typing and BSE. Biosepar Ges. für Medizin- und Labortechnik mbH PHARMA ANIMAL HEALTH BIOSEPAR is driving excellence in sample preparation for parasitologic diagnostics since 1987. With the vision to make parasitologists’ life easier, BIOSEPAR has revolutionized parasitological stool diagnostics with stan- dardized, hygienic, ready-to use kits and non-toxic, environmentally friendly reagents in both, human and veterinary medicine. The flagship product ParasiTrap® was followed by FixSepar® ECO and while increasing its global reach the company continues driving innovation. Biophyll GmbH PHARMA SUPPLIER AND TRADE Biophyll has over 25 years of experience in sourcing and manufacturing of biological products of animal, human, and plant origin. We assess the specific needs of our customers to provide tailored product solutions for pharmaceutical, diagnostic, and scientific purposes. - Access to new and rare biological products sourced worldwide - Supply of quality and traceability documentation - Regulatory support in import, export, and registration mat- ters - Individually designed transport logistics concepts 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Landsberger Str. 234 D-80687 München Phone: +49 (0) 89 324799-50 E-Mail: contact@biontex.com Internet: www.biontex.com Heidemannstr. 164 D-80939 München Phone: +49 (0) 89 31884-0 E-Mail: info@bio-rad.de Internet: www.bio-rad.com Am Industriepark 2A D-84453 Mühldorf E-Mail: mail@biosepar.de Internet: www.biosepar.de Winkl 4 D-84378 Dietersburg Phone: +49 (0) 8565 964961 Internet: www.biophyll.com 57

NEW: Wachstumsfonds Bayern W W W. B AY E R N K A P I TA L . D E Bayern Kapital GmbH | Ländgasse 135 a | 84028 Landshut Phone +49 (0)871 92325-0 | info@bayernkapital.de Your high tech enterprise is looking for equity capital? Bayern Kapital offers: • seed fi nance equity capital, for R&D, market launch and growth • co-investments with partners • many years of experience in fi nancing • access to strong network • later stage venture capital Carl Zeiss Microscopy GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture ZEISS Research Microscopy Solutions is the world’s only one-stop manufac- turer of light, electron, X-ray and ion microscope systems and offers solu- tions for correlative microscopy. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as educa- tion and clinical practice. The unit is headquartered in Jena. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment of the ZEISS Group. CASCAT GmbH INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotech- nology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus. Kistlerhofstr. 75 D-81379 München Phone: +49 (0) 89 909000-800 E-Mail: microscopy@zeiss.com Internet: www.zeiss.com/microscopy Europaring 4 D-94315 Straubing Phone: +49 (0) 9421 7855 20 Internet: www.cascat.de 59 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Centronic GmbH BIOTECH DEVICES & REAGENTS Keywords: Analytical Chemistry, Medicinal Chemistry, In-Vitro-Diagnostics, Clinical Diagnostics Centronic GmbH is a german manufacturer and distributor of a big range of high qualitative clinical chemistry and immunoturbidimetric reagents for the medical diagnosis of enzymes, electrolytes, substrates, lipids and specific proteins. The portfolio is completed with corresponding controls, calibrators, Latex and Salmonella reagents and cleaning solutions for many analysers. Our Quality Management System is certified according EN ISO 13485:2016 by the TÜV. Cfm Oskar Tropitzsch GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Pharmacology, Antibiotics, Fine Chemicals/Reagents, AntibodyDrugConjugate ADC, Natural Compounds, Drug Development, Drug Delivery Cfm Oskar Tropitzsch is your reliable and GDP-Certified partner for: Small scale (API) manufacturing (nonGMP/cGMP) Contract synthesis (nonGMP/ GMP) Small molecules (> 700 substances) Phytochemicals (> 1000 substanc- es) Phyto-Reference Substances Pharmaceutical raw materials Excipients HPAPIs - Cytotoxins - Payloads for ADCs. Sourcing of APIs Cfm Oskar Tropitzsch GmbH assists the pharmaceutical and biotech industry in sourcing and producing APIs and Excipients. Charles River Laboratories, Research Models and Services, Deutschland GmbH CRO Keywords: Drug Delivery At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future. Am Kleinfeld 11 D-85456 Wartenberg Phone: +49 (0) 8762 7243-00 E-Mail: info@centronic-gmbh.com Internet: www.centronic-gmbh.com Adalbert-Zoellner-Str. 1 D-95615 Marktredwitz Phone: +49 (0) 9231 9619-0 E-Mail: info@cfmot.de Internet: www.cfmot.de Sandhofer Weg 7 D-97633 Sulzfeld Phone: +49 (0) 9761 406 0 Fax: +49 (0) 9761 406 60 E-Mail: dbestell@de.crl.com Internet: www.criver.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 61

Climedo Health GmbH BIOTECH BIOINFORMATICS Keywords: Automation, Cell Therapy, Oncology, Clinical Trial Management and Monitoring, Devices, Regulatory Affairs, Data Management Climedo’s mission is to bring the best treatment to every patient by empow- ering healthcare professionals with intelligent software solutions. Together with Europe’s leading hospitals, they have developed a cloud-based plat- form for cutting-edge clinical validation and post-market surveillance of medical devices and pharmaceutical products. By digitally connecting all stakeholders (medical device manufacturers, pharma companies, CROs, hospitals and patients), Climedo allows for increased performance, better cost-effi ciencies - and ultimately - accelerated medical innovation. Clinipace GmbH CRO Keywords: Drug Development, Regulatory Affairs, Medical Writing, Orphan Drug, Oncology, Clinical Trial Management and Monitoring, Data Management and Biostatistics Clinipace is a global, mid-size contract research organisation (CRO) provid- ing a comprehensive suite of services, technology, and people. We have the global reach and cutting-edge systems of a large CRO, but the agility and speed of a smaller organisation. Clinipace understands the complexities involved in clinical development and we take a personal and consultative approach through our knowledgeable staff who can navigate both the opera- tional and regulatory challenges that may arise. Clinrex GmbH CRO Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting ser- vices and training in the of areas GCP, Quality Management and Project Management for clinical trials. GCP/Quality Management Consulting - GCP gap analyses - Inspection readiness/Audits - SOP development/streamlining - Interface sponsor/CRO - Investigator Initiated Trials (IITs) Training (Smart Training® or customised in-house training) - GCP for Sponsors, CROs or On-site Personnel - Project Management/Working with CROs - NIS Schellingstr. 109a D-80798 München Phone: +49 (0) 89 32209394 0 E-Mail: info@climedo.de Internet: www.climedo.de Helfmann-Park 10 D-65760 Eschborn Phone: +49 (0) 6196 7009 - 0 E-Mail: contact@clinipace.com Internet: www.clinipace.com PF 1223 D-85572 Neubiberg Phone: +49 (0) 89 9292 87-0 E-Mail: info@clinrex.com Internet: www.clinrex.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 63

Coriolis Pharma Research GmbH CRO Keywords: R&D Service, Peptide/Protein, Vaccines, Antisense/Nucleotides, Analytical Chemistry Coriolis is a globally operating and world-leading contract research organiza- tion in formulation development of (bio)pharmaceutical drugs and vaccines, including proteins, peptides, antibodies, RNA/DNA, VLPs, virus-based ATMPs and GMOs (up to BSL-2). Coriolis is highly experienced in biopharmaceutical characterization by using innovative and state of the art analytical technol- ogies to support trouble-shooting, higher order structure characterization studies, particle forensic and GMP release. Covance Clinical Development GmbH CRO Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development Covance Inc. is the worlds most comprehensive drug development compa- ny. We are dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical & commer- cialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing. Creative Instruments GmbH BIOTECH DEVICES & REAGENTS Keywords: PCR, Automation, Devices Creative Instruments develops and manufactures customized solutions for lab- oratory automation, automation analysis for diagnostics and biotechnology as well as for measurement technology in close cooperation with the customer. The focus is on precision engineering, chemical and liquid handling, particularly in the optical detection and related evaluation. Its product portfolio includes now analyt- ical devices as Real-time PCR Cycler and temperature control systems. CRELUX GmbH - a WuXi AppTec company BIOTECH PRECLINICAL SERVICES Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis CRELUX is part of HitS platform of WuXi AppTec and provides one-stop solutions for clients seeking premium drug discovery services. We enable early drug discovery, which starts by providing high quality protein and con- tinues with target validation, hit finding (fragment or DNA encoded library screenings) and hit confirmation (biophysics, biochemistry). Importantly, our clients can obtain structural elucidation of their target at atomic precision from X-ray crystallography, Cryo-EM or NMR. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Fraunhoferstr. 18b D-82152 Martinsried Phone: +49 (0) 89 41 77 60-0 E-Mail: info@coriolis-pharma.com Internet: www.coriolis-pharma.com Carl-Wery-Str. 42 D-81739 München Phone: +49 (0) 89 9210930 E-Mail: wolfgang.schlaeger@covance.com Internet: www.covance.com Holzhofstr. 19 D-82362 Weilheim Phone: +49 (0) 881 92 77 89 0 E-Mail: info@creative-instruments.de Internet: www.creative-instruments.de Am Klopferspitz 19 a D-82152 Martinsried Phone: +49 (0) 89 700760-0 E-Mail: crelux_office@wuxiapptec.com Internet: www.crelux.com 65

CSO Pharma Consulting GmbH CRO Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigiliance, Medical Writing, Laboratory CSO Pharma provides reliable pharmacovigilance services, professional medical affairs support and successful QM/GDP consulting. We run our own quality management system and offer our customers reliable services and processes based on international standards. You can benefit from our exten- sive experience from audits and inspections and our comprehensive knowl- edge of present legal requirements. Curadis GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Bachbauernstrasse 1 D-81241 München Phone: +49 (0) 89 20335359 E-Mail: info@cso-pharma.eu Internet: www.cso-pharma.eu The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The com- pany is developing a novel substance for breast cancer and a substance for prostate cancer. Merianstraße 26 D-90409 Nürnberg Phone: +49 (0) 700 - 1447 1447 E-Mail: info@curadis.eu Internet: www.curadis.eu Cytophorics GbR BIOTECH DEVICES & REAGENTS Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro- Diagnostics The Cytophorics technology enables a variety of applications in the pharma- ceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms. CYTOX, biologische Sicherheitsprüfungen BIOTECH DEVICES & REAGENTS Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture CYTOX provides biological testing service for the medical device and phar- maceutical industry by using in vitro toxicological testing procedures accord- ing to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications. An der Rehwiese 20 D-81375 München Phone: +49 (0) 89 30725921 E-Mail: info@cytophorics.com Internet: www.cytophorics.de Gottlieb-Keim-Str. 60 D-95448 Bayreuth Phone: +49 (0) 921 1511-254 E-Mail: info@cytox.de Internet: www.cytox.de 67 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Denk Pharma GmbH & Co. KG PHARMA & CHEMICAL INDUSTRY In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany. Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally oper- ating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948. DiaServe Laboratories GmbH BIOTECH DEVICES & REAGENTS DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manu- facturers and clinical laboratories. Dojindo EU GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Fine Chemicals/Reagents Prinzregentenstraße 79 D-81675 München Phone: +49 (0) 89 2300 29-0 E-Mail: mathias.seidel@denkpharma.de Internet: www.denkpharma.de Seeshaupter Str. 27 D-82393 Iffeldorf Phone: +49 (0) 8856 8036-05 E-Mail: contact@diaserve.de Internet: www.diaserve.de Dojindo produces over 500 well-known products used by research organiza- tions in the world. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activi- ties as well as improving its information-gathering network. Dojindo is ready for offering state-of-the-art products because our creative researchers are working continuously to meet tomorrow’s research needs. Leopoldstr. 254 D-80807 München Phone: +49 (0) 89 3540-4805 E-Mail: info@dojindo.eu.com Internet: www.dojindo.eu.com DoNatur GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Rheumatoid Arthritis DoNatur GmbH develops new therapeutics from herbal extracts with tradi- tionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has success- fully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases. Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 856625-55 E-Mail: info@donatur.de Internet: www.donatur.de 69 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ebenbuild GmbH DIGITAL HEALTH Keywords: Personalized Medicine, Respiratory Diseases, Pneumology, Biomarker Discovery & Development, Informatics, Imaging, R&D Service Every year, six million patients worldwide are mechanically ventilated due to Acute Respiratory Distress Syndrome (ARDS), e.g. caused by Corona. Two million die. Ebenbuilds deep-tech software harnesses cutting-edge phys- ics simulation and computer vision to generate unprecedented data of the patients lung. A fi rst of a kind precision tool, it will enable physicians to pro- vide better, personalized protective ventilation therapy for ARDS, improving the patients odds of survival and recovery. Eisbach Bio GmbH BIOTECH DEVICES & REAGENTS Eisbach develops medicines that target chromatin regulatory mechanisms essential to tumors. Our novel targets and best-in-class drug discovery allow us to develop a pipeline of impactful medicines. Since a tumor’s genome constantly evolves, cancers can be diffi cult to target. We identifi ed the engines that drive all genome rearrangements. Our unique screening platform has generated fi rst-in-class inhibitors that target the key vulnerability in genetically- defi ned tumors. Electrochaea GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Electrochaea offers a nationally and internationally patented power-to-meth- ane key technology based on biocatalysis, which cost-effectively recycles CO2 and at the same time produces carbon-neutral methane that can be stored and used at will from excess electrical energy. The fi rst pilot plant on an industrial scale is operating successfully in Denmark. Further plants were opened in Solothurn, CH, and Colorado, US in 2019. Plants of more than one gigawatt of capacity are targeted by 2025. ELLA Biotech GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technolo- gy and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our custom- ers and partners. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Schinkelstraße 44 c/o Dr. Kei Müller D-80805 München Phone: +49 (0) 89 289 15265 E-Mail: info@ebenbuild.com Internet: www.ebenbuild.com/index.html Am Klopferspitz 19 D-82152 Martinsried Internet: www.eisbach.bio Semmelweisstraße 3 D-82152 Planegg Phone: +49 (0) 89 3249 3670 E-Mail: info@electrochaea.com Internet: www.electrochaea.com Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 7093 9316 E-Mail: info@ellabiotech.com Internet: www.ellabiotech.com 71

Eurofins BioPharma Product Testing Munich GmbH BIOTECH PRECLINICAL SERVICES Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology Eurofins BioPharma Product Testing Munich is part of the world‘s largest network of testing laboratories providing comprehensive laboratory ser- vices to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, med- ical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich. Eurofins Genomics BIOTECH DNA/PROTEIN ANALYTICS Keywords: Genomics, NGS, PCR, Antisense/Nucleotides Behringstr. 6/8 D-82152 Martinsried Phone: +49 (0) 89 899650-0 E-Mail: info-munich@eurofins.com Internet: www.eurofins.de Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene syn- thesis. Anzinger Straße 7a D-85560 Ebersberg Phone: +49 (0) 8092 8289-0 E-Mail: info-eu@eurofins.com Internet: www.eurofinsgenomics.com Evanium Healthcare GmbH PHARMA & CHEMICAL INDUSTRY Alcohol consumption and the associated health-risks as well as the Hangover are common problems with a negative impact on the consumer as well as the society. Evanium Healthcare is active in alcohol research, with the company pursuing a dietary approach. By the means of custom galenic formulation of the key ingredients Evanium Healthcare could develop tablets for oral consumption and produce them on a pilot system. Wide-ranging patent applications protect the product from imitation and enable a strong market postition. Evotec (München) GmbH BIOTECH PRECLINICAL SERVICES Keywords: Cell Therapy, Metabolomics, Biomarker Discovery & Development, Bioinformatics, Small Molecules, Proteomics, Genomics Evotec is a leading player in the drug discovery and development field. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company’s headquarters are located in Hamburg, Germany with 13 further operational sites in Europe and the USA and more than 2,500 employees worldwide. Evotec (München) GmbH is the Company’s centre of excellence for proteomics, biomarker and metabolomics services. Am Biopark 13 D-93053 Regensburg E-Mail: kontakt@evanium.de Internet: www.evanium.de/ Am Klopferspitz 19a D-82152 Martinsried Phone: +49 (0) 89 4524465-0 E-Mail: info@evotec.com Internet: www.evotec.com 75 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

FGK Clinical Research GmbH CRO Keywords: CRO/CMO, Drug Development, Cell Therapy, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring FGK is a Europe-based CRO with offices in DE (HQ), PL, CZ and HU, offer- ing full service for all phases of clinical trials. Our international client base includes biotech, medical device and pharma companies. With extensive experience in all major therapeutic areas and 150+ highly qualified medical, scientific and regulatory experts we can guide you through the clinical devel- opment process, from planning and approval up until the final report. FGK Pharmacovigilance GmbH CRO Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies’ obliga- tions in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a stand- alone center of product vigilance on national, international or global level. FLUICS GmbH BIOTECH DEVICES & REAGENTS Keywords: sample tracking, labeling, mobile databas Heimeranstr. 35 D-80339 München Phone: +49 (0) 89 893 119-0 E-Mail: info@fgk-cro.com Internet: www.fgk-cro.com Heimeranstraße 35 D-80339 München Phone: +49 (0) 89 893 119-0 E-Mail: info@fgk-pv.com Internet: www.fgk-pv.com FLUICS CONNECT helps modern research labs to keep their sample inven- tory up to date. With our mobile app and an internet-ready printer connect- ed to an online database we offer a convenient solution to print and track smear proof, QR-coded cryo labels. It takes just 1 minute to watch how it works: https://go.fluics.com/teaser. Fürstenstraße 15 D-80333 München Phone: +49 89 71690877 E-Mail: connect@fluics.com Internet: www.fluics.com FoodChain ID Testing GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Agrobiotechnology, NGS FoodChain ID Testing GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identifica- tion, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed. Am Mittleren Moos 48 D-86167 Augsburg Phone: +49 (0) 821 74776-30 E-Mail: info@foodchainid.de Internet: www.foodchainid.com/de 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 77

GBA PHARMA GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Laboratory, Analytical Chemistry, R&D Service GBA Pharma Labs run three GMP-certified and FDA-inspected sites in Germany with more than 160 highly qualified employees and over 4,500 m2 of lab space. Our locations for analytical services support domestic and international customers, whether from the private industry or research insti- tutions, with scientific and technical solutions for the development, approval process, and quality control throughout every step of the product lifecycle. GBN Systems GmbH BIOTECH & MEDTECH DEVICES & REAGENTS For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conduc- tor industry and automation technology. Our product range: From custom- ized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics. Fraunhoferstraße 11a D-82152 Planegg-Martinsried Phone: +49 (0) 89 899229-0 E-Mail: info@gba-pharma.com Internet: www.gba-pharma.com Fellnerstrasse 2 D-85656 Buch am Buchrain Phone: +49 (0) 8124 5310-0 E-Mail: info@gbn-systems.com Internet: www.gbn-systems.com 0-9 A B C D E F G H I J K L

Gen-Plus GmbH & Co. KG CRO Keywords: Laboratory, R&D Service, Drug Development Gen-Plus GmbH & Co.KG provides solutions for challenging needs in pharmaceutical development and is a state-of-the-art CRDO. We develop tailor-made fomulation and technology concepts (NCE, value-added-Ge- nerics, OTC) for solid/semisolids, non-steril liquids, patches and thin films from early idea to IMP production under GMP. Further in-house capabilities: narcotics & high potent handling (isolators), 2D&3D API printing, high-tech analytics incl. skin permeation. Gilead Sciences GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has opera- tions in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. GILYOS GmbH CRO Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development GILYOS is a contract development solution provider with more than 20 years of experience in pharmaceutical freeze drying. GILYOS` key business is consultancy and hands-on development services. Typical services include formulation development of small molecules and proteins, process optimi- zation and analytical characterization. Further, GILYOS has a very strong expertise in scale-up and technical transfer of freeze drying cycles, including troubleshooting of established products (scale down). gimbio mbH Gesellschaft für Informations- management in der Biotechnologie BIOTECH BIOINFORMATICS Keywords: Automation, Data Management Gimbio GmbH offers innovative products and solutions in bioprocess tech- nology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the informa- tion gathering and processing, the development and application of innova- tive online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Staffelseestraße 6 D-81477 München Phone: +49 (0) 89 780 179 40 E-Mail: info@gen-plus.de Internet: www.gen-plus.de Fraunhoferstr. 17 D-82152 Martinsried Phone: +49 (0) 89 899890-0 E-Mail: info@gilead-sciences.de Internet: www.gilead.com Friedrich-Bergius-Ring 15 D-97076 Würzburg Phone: +49 (0) 931 907056-78 E-Mail: info@gilyos.com Internet: www.gilyos.com Weihenstephaner Berg 4 D-85354 Freising/Weihenstephan Phone: +49 (0) 8161 986 4480 E-Mail: info@gimbio.de Internet: www.gimbio.de 81

GlaxoSmithKline GmbH & Co. KG PHARMA & CHEMICAL INDUSTRY Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology GSK is a science-led, globally operating healthcare company with a special purpose: to help people do more, feel better, live longer. Our goal is to be one of the worlds most innovative, best performing and trusted healthcare companies. GSK is setting milestones in healthcare prevention with a com- prehensive portfolio of vaccines, respiratory and additionally in Oncology . Via our affi liate ViiV Healthcare, we are also involved in the area of HIV. GNA Biosolutions GmbH BIOTECH DNA/PROTEIN ANALYTICS Keywords: Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, Molecular Diagnostics, Devices, New Materials, Other Diagnostics GNA Biosolutions GmbH was founded in 2010 as a spin-off from Ludwig- Maximilians-Universität, Munich. The company employs 40 people today. GNA develops instruments, consumables and tests for fast molecular diag- nostics, based on its proprietary technology, Pulse Controlled Amplifi cation (PCA). PCA can transform molecular diagnostics by enabling the develop- ment of testing platforms that can be used outside of the traditional labora- tory setting. Gotham Therapeutics, NY/Munich BIOTECH THERAPEUTICS & DIAGNOSTICS Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By chang- ing the activity of proteins that modify messenger RNA, Gotham aims to develop new treatment options for patients suffering from cancers, auto-im- mune and neurodegenerative diseases. The team is applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical fi eld. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Prinzregentenplatz 9 D-81675 München Phone: +49 (0) 89 360 440 E-Mail: service.info@gsk.com Internet: www.de.gsk.com Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 998 207-180 E-Mail: info@gna-bio.com Internet: www.gna-bio.com 430 East 29th Street Alexandria Center for Life Science, Suite 1435E USA-NY 10016 New York E-Mail: bzech@gothamtx.com Internet: www.gothamtx.com 83

HMNC Brain Health GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development HMNC is a biopharma company developing novel treatments for depression and anxiety: Proprietary gene-based companion tests support the decision which drugs optimize treatment effects. Our portfolio includes investigation- al drugs targeting stress systems in the brain. A novel formulation of ket- amine holds promise to become prime option for treatment resistant depres- sion. The myGeneCode1-test informs whether a given antidepressant passes the blood-brain barrier. The test is already on the market. Human Tissue and Cell Research-Services (HTCR) GmbH BIOTECH PRECLINICAL SERVICES Keywords: Biomarker Discovery & Development, Bioprocessing, Tissue Engineering/Cell Culture, Toxicology HTCR-Services (HSG) develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used for prognosing metabolism of novel drugs and for in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products, HSG provides to the scientifi c community and pharmaceutical industry an out- standing in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extend. HTI bio-X GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Automation HTI bio-X GmbH is an engineering supplier for products and technical ser- vice. We are developing customized solutions of instruments and automa- tions. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expand- able with many modules e.g. for labelling, barcode reading, fi lling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements. Wilhelm-Wagenfeld-Str. 20 D-80807 München Phone: +49 (0) 89 36090200 E-Mail: info@hmnc.de Internet: www.hmnc.de Am Klopferspitz 19 D-82152 Martinsried Phone: +49 (0) 89 520 59694 E-Mail: info@HTCR-services.com Internet: www.htcr-services.com Am Forst 6 D-85560 Ebersberg Phone: +49 (0) 8092 2092-0 E-Mail: info@hti-bio-x.com Internet: www.hti-bio-x.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 85

ImevaX GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Infectious Diseases, Industrial Biotechnology, In-Vitro-Diagnostics, Clinical Diagnostics, Biomarker Discovery & Development ImevaX GmbH, founded in 2013, is a Munich based life science company focussed on novel infection diagnosis. Current product in development is an innovative H. pylori rapid test that combines unprecedented sensitivity, specificity and speed. It determines the presence of two specific antibodies to H. pylori, FliD and CagA, that allow a risk-stratification into low- and high- risk groups for development of gastric cancer. ImevaX owns the global patent for the detection of antibody marker FliD. IMGM Laboratories GmbH BIOTECH & PHARMA PRODUCTION Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, Pharmacogenomics IMGM Laboratories are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover bio- marker discovery, pharmacogenetics, metagenomics and biodistribution studies of nucleic acid compounds. In close collaboration to our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification. immatics biotechnologies GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Development, Cell Therapy, Personalized Medicine, Immune Therapy, Oncology, Genomics, Proteomic Immatics combines the discovery of true targets for cancer immunothera- pies with the development of the right Tcell receptors to enable a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical indus- try. We are committed to delivering the power of T cells - unlocking new avenues for patients in their fight against cancer. Sendlinger Str. 60 D-80331 München Phone: +49 (0) 89 4140 2477 E-Mail: info@imevax.com Internet: www.imevax.com Lochhamer Str. 29a D-82152 Martinsried Phone: +49 (0) 89 452 4667-0 E-Mail: info@imgm.com Internet: www.imgm.com Machtlfinger Straße 11 D-81379 München Phone: +49 (0) 89 540415-0 E-Mail: info@immatics.com Internet: www.immatics.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 87

Implen GmbH BIOTECH DEVICES & REAGENTS Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices Implen is a privately held corporation that is a leading supplier for spectros- copy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research. Independent Data Lab BIOTECH BIOINFORMATICS Genomic data has become an essential part of almost every project in molecular biology and medicine. Unfortunately, high rate of rotation of personnel in academic environment has made it diffi cult to maintain collab- orations for projects that often can last for years. At IDL we are committed to making sure every dataset receives the most thorough attention, and makes it’s contribution to the progression of science. INCYTON GmbH BIOTECH DEVICES & REAGENTS Keywords: Oncology, Drug Development, Toxicology, R&D Service, In-Vitro- Diagnostics, Imaging, Bioanalytics INCYTON multi-sensor systems monitor different cellular key parameters simultaneously, in real time and label free. Our technology records each event, giving the user full control at every time-point without the need to be constantly present. A highly automated testing process reduces the time spent carrying out even the most complex assays. INCYTON smart technolo- gies are combined in one housing creating a global environment control and reducing the risk of contamination and variations. Schatzbogen 52 D-81829 München Phone: +49 (0) 89 7263718-0 E-Mail: info@implen.de Internet: www.implen.de Josef-Frankl-Straße 5A D-80995 München Internet: www.independentdatalab.com Am Klopferspitz 19a D-82152 Planegg-Martinsried E-Mail: info@incyton.com Internet: www.incyton.com Infors GmbH BIOTECH DEVICES & REAGENTS INFORS HT is your specialist for bioreactors, shaker incubators and biopro- cess software. We offer the right solutions for the cultivation of microorgan- isms and cell cultures: Customer specifi c bioreactors and incubation shakers including qualifi cation, parallel bioprocesses, and integration of all your bioprocesses in one software platform. Close customer relationships, high quality, innovation and fl exibility are our greatest strengths. Dachauer Str. 6 D-85254 Einsbach Phone: +49 (0) 8135 8333 E-Mail: infors.de@infors-ht.com Internet: www.infors-ht.com 89 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Intana Bioscience GmbH BIOTECH PRECLINICAL SERVICES Keywords: Drug Development, R&D Service Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candi- dates, and by supporting drug discovery and development efforts from tar- get validation to clinical testing. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements. Lochhamer Str. 29 a D-82152 Martinsried Phone: +49 (0) 89 895 572-80 E-Mail: info@intana.de Internet: www.intana-bioscience.de inveox GmbH IT, DIGITAL HEALTH Keywords: Other Diagnostics, Data Management, Devices, Clinical Diagnostics, Laboratory, Imaging, Tissue Engineering/Cell Culture inveox has the goal of making cancer diagnosis faster, safer, and more reli- able. In todays labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addi- tion, we create the lab of the future by bringing big data, artificial intelli- gence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer. Invitrocue Europe AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Bioanalytics, In-Vitro-Diagnostics, Personalized Medicine, 3D-Structural Analysis, Other Diagnostics, Tissue Engineering/Cell Culture, Laboratory Invitrocue Europe AG is an innovative leading healthcare bio-analytic com- pany, that specialises in ex-vivo 3D cell culture models such PDOs as well as in-vivo models by producing HiMice™ as promising tools for personalized cancer treatment. IVQ imparts to the industry valuable knowledge in creating better, faster and more affordable disease treatments. Intercept Pharma Deutschland GmbH PHARMA & CHEMICAL INDUSTRY Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, New York, Intercept now has opera- tions in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the ‚liver community‘. Lichtenbergstraße 8 D-85748 Garching bei München Phone: +49 (0) 89 57847601 E-Mail: info@inveox.com Internet: www.inveox.com Hildegardstr. 9 D-80539 München Phone: +49 (0) 89 998209483 E-Mail: contact.de@invitrocue.com Internet: www.invitrocue.com/ Rosenheimer Str. 52 D-81669 München Phone: +49 (0) 89 4111 124 11 E-Mail: info-DE@interceptpharma.com Internet: www.interceptpharma.com/about/germany 91 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ISAR Bioscience GmbH BIOTECH PRECLINICAL SERVICES Keywords: Industrial Biotechnology, Drug Development, Tissue Engineering/ Cell Culture, Nutraceuticals, Neuro-Degeneration, Cell Therapy, Biomarker Discovery & Development ISAR Bioscience GmbH is a translational research company. We overcome current limitations of stem cell research in order to advance development of novel therapeutics and industrial biotechnology products. We use human iPSC and genome editing technologies to build the next generation of dis- ease models and cell-based models for biotechnology applications. ISAR forges strategic partnerships with industry partners and translates academic achievements and ideas into industrial solutions and products. iThera Medical GmbH BIOTECH DEVICES & REAGENTS Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology iThera Medical develops and markets a novel in-vivo biomedical imaging technology, “MSOT” = multi-spectral opto-acoustic tomography. MSOT uti- lizes the photo-acoustic effect to visualize and quantify anatomical, function- al and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics. ITM Isotopen Technologien München AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radio- pharmaceuticals and radioisotopes for use in cancer treatment. ITM’s main objectives are to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health eco- nomics through a new generation of Targeted Radionuclide Therapies. Semmelweisstr. 5 D-82152 Planegg Phone: +49 (89) 3564 754-00 E-Mail: info@isarbioscience.de Internet: www.isarbioscience.de Zielstattstr. 13 D-81379 München Phone: +49 (0) 89 700 7449-0 E-Mail: info@ithera-medical.com Internet: www.ithera-medical.com Lichtenbergstr. 1 D-85748 Garching Phone: +49 (0) 89 329 8986 600 E-Mail: info@itm.ag Internet: www.itm.ag 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 93

KLIFOVET AG CRO Keywords: Pharmacovigiliance, Regulatory Affairs, Drug Development, Data Management and Biostatistics, Clinical Trial Management and Monitoring KLIFOVET AG is a full service veterinary CRO and Regulatory Consultancy and provides the following services: evaluation of research projects, Regulatory Consultancy, Life Cycle Management & PhV, Preclinical and Clinical Studies, Quality Assurance, Data Management and more. Experienced in all species, we manage the development of VMPs & Feed/ Feed Additives in every step. Multiple Animal Pharm Awards in 2006, 2015 and ‘Best Service Company’ for 2019 show our long term commitment to our customers. kmbs BIOTECH DNA/PROTEIN ANALYTICS Keywords: Genomics, PCR Geyerspergerstr. 27 D-80689 München Phone: +49 (0) 89 580 082-0 E-Mail: info@klifovet.com Internet: www.klifovet.com kmbs care for organismic studies e.g. in Wildlife Biology, Phylogeny, Taxonomy, and Conservation Biology to clear up specimens’ identities by means of DNA analyses (sample preparation, PCR, DNA sequencing) for purposes like identifying species, detecting animal pre-/absence, delimiting species boundaries, resolving species relations a.s.o. Off the lab, mapping species inventories or searching for organisms including electro fishing is our business. Ferdinand-Zwack-Str. 39 D-85354 Freising Phone: +49 (0) 8161 205957 E-Mail: info@kmbioservices.de Internet: www.kmbioservices.de Laboklin GmbH & Co KG – Unternehmensbereich Labogen BIOTECH THERAPEUTICS & DIAGNOSTICS Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, hae- matology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more. Steubenstr. 4 D-97688 Bad Kissingen Phone: +49 (0) 971 7202-0 E-Mail: mueller@laboklin.de Internet: www.laboklin.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 95

Lead Discovery Center GmbH, LDC - Abteilung Antikörper BIOTECH PRECLINICAL SERVICES The lead discovery center GmbH was founded in 2008 by the Max Planck Society in order to exploit the potential of the excellent basic research for the development of new, urgently needed drugs. The Lead Discovery Center collects promising academic research projects and develops them further into pharmaceutical lead structures (Proof-of-concept in model systems). In close collaboration with leading academic and industrial partners the Lead Discovery Center develops an extensive project portfolio in the fields of small molecules (Dortmund) and therapeutic antibodies (Planegg) with high medical and commercial potential. leon-nanodrugs GmbH PHARMA & CHEMICAL INDUSTRY Keywords: Drug Development, Drug Delivery, Peptide/Protein, Small Molecules leon is leading the way in expediting APIs to deliver improved stability, increased solubility and enhanced bioavailability, revitalizing forgotten formulations and breathing new life into generics. leon provides complete development services for the international market from concept to CTM and commercial production. leons patented microjet reactor MJR® technology platform offers access to the next generation of SMART nano-particles™and nano-formulated drugs. LEUKOCARE AG BIOTECH DEVICES & REAGENTS LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. Our tech- nologies are employed in collaborations with partners in the field of vac- cines, therapeutic proteins, and biologic device combination products. They provide manifold benefits as improved shelf-life, Terminal sterilization and Significant production cost savings. LEUKOCARE provides development ser- vices based on fee for service during implementation of its technologies. Semmelweisstr. 5 D-82152 Planegg Phone: +49 (0) 231 97 42 70 00 Fax: +49 (0) 231 97 42 70 39 E-Mail: info@lead-discovery.de Internet: www.lead-discovery.de Kopernikusstr. 9 D-81679 München Phone: +49 (0) 89 4142 4889-0 E-Mail: info@leon-nanodrugs.com Internet: www.leon-nanodrugs.com Am Klopferspitz 19 D-82152 Martinsried/Munich Phone: +49 (0) 89 7801665-0 E-Mail: info@leukocare.com Internet: www.leukocare.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 97

Loewe® Biochemica GmbH BIOTECH DEVICES & REAGENTS Keywords: Agrobiotechnology, ELISA/EIA LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nema- todes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR). Lophius Biosciences GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases Lophius mission is to transform treatment paradigms and patient manage- ment with novel molecular diagnostic solutions for life threatening infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB) with a proprietary blood-based multi-marker solution to improve TB infection detection and enable differential diagnosis. Lophius also markets a clinically validated CE-marked IVD to individualize transplant patient man- agement by personalized CMV risk stratification. LRE Medical GmbH MEDTECH Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics LRE Medical GmbH is a leading developer and manufacturer of medical, in vitro diagnostic (IVD) and life sciences instrumentation for OEM custom- ers. For more than 45 years LRE provides full turnkey projects ‘One Stop Shop’ solutions for Point-of-Use and Laboratory incl. MDx (Engineering, Manufacturing, After Sales Service and Lifetime Product Support) for the development and manufacturing of innovative devices in compliance with ISO 13485, IVDR, FDA CFR Part 820 for Class I-III Medical Devices. Luye Pharma AG PHARMA & CHEMICAL INDUSTRY Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry Luye Pharma AG Miesbach is one of the largest independent manufacturers of transdermal delivery systems in Europe with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone treatments. Luye Pharma AG also acts as the EU hub for Luye Pharma Group’s development efforts in R&D, manufac- turing, international registration, and market promotion of new formulation products to international standards. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z LOEWE® Mühlweg 2 a D-82054 Sauerlach Phone: +49 (0) 8104 616-20 E-Mail: service@loewe-info.com Internet: www.loewe-info.com Am BioPark 13 D-93053 Regensburg Phone: +49 (0) 941 6309 197-0 E-Mail: request@lophius.com Internet: www.lophius.com Georg-Brauchle-Ring 89 D-80992 München Phone: +49 (0) 89 354803-47 E-Mail: info@lre.de Internet: www.lre.de Am Windfeld 35 D-83714 Miesbach Phone: +49 (0) 8025 2867-0 E-Mail: info@luyepharma.eu Internet: www.luyepharma.eu 99

MedPharmTec GmbH CRO Keywords: Medical Writing, Pharmacovigilance, Regulatory Affairs MedPharmTec is a service provider for pharmaceutical medicine. Our customers: pharmaceutical industry and companies in the biotechnology, medical technology and food industries. Our services: Proofreading / proof- reading by specialist and Product information / Creation and maintenance of drug information / Authorization maintenance (e.g. creation of PSURs) / Consulting for pharmacovigilance in Clinical Trials and NIS / Preparation and Submission of Ethical Applications and official registrations metabion BIOTECH DEVICES & REAGENTS Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality prod- ucts and services. Metabion offers production of a wide range of synthetic DNA and RNA oligonucleotides according to customers’ needs as well as the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion’s business philosophy and key to its popularity at the same time. MetaHeps GmbH BIOTECH PRECLINICAL SERVICES Keywords: Toxicology, Drug Development MetaHeps® is an innovative service provider specialized to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank. Neuhauser Str. 47 / IV D-80331 München Phone: +49 (0) 89 354 998-0 E-Mail: office@medpharmtec.de Internet: www.MedPharmTec.de Semmelweissstr. 3 D-82152 Martinsried Phone: +49 (0) 89 899363-0 E-Mail: info@mymetabion.com Internet: www.metabion.com Am Klopferspitz 19 D-82152 Martinsried Phone: +49 89 7007 6614 E-Mail: info@metaheps.com Internet: www.metaheps.com 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 101

MINITÜB GmbH BIOTECH AGRO, FOOD, ENVIRONMENT Minitüb is an international established system supplier for assisted repro- duction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its participation in MWM Biomodels GmbH, a spin-off company of LMU Munich, Minitüb is also engaged in the development and character- ization of transgenic large animal models for biomedical research. Current projects focuse on genetically modifi ed pigs for xenotransplantation, trans- genic pig models of diabetes mellitus, muscular dystrophy and immunode- fi ciency. mk2 Biotechnologies BIOTECH DNA/PROTEIN ANALYTICS Keywords: R&D Service, Bioanalytics, Industrial Biotechnology mk2 Biotechnologies develops, produces and investigates peptides at high- est purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances. MLL Münchner Leukämie Labor GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research. An interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis and includes: cytomorphology, chro- mosome analysis, immunophenotyping, cytogenetics, FISH, and molecular genetics. MLL performs also WGS. Several workfl ows are already supported by AI. This combination gives medical professionals an essential foundation to ensure ideal patient care. Molecular Machines & Industries GmbH BIOTECH DEVICES & REAGENTS Keywords: Microscopy, Molecular Diagnostics, Devices MMI Microdissection, Micromanipulation and Imaging MMI is the leading provider of unique technologies for microdissection, micromanipulation, and imaging with a wide range of clinical and research applications. I.e. Capillary-based selective isolation of single cells (CellEctor), Pico-cut laser microdissection to isolate cells in tissue (CellCut), Microscopy-integrated Whole Slide Imaging (CellScan), Optical tweezers to quantify biological forc- es (CellManipulator). 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Haupstr. 41 D-84184 Tiefenbach Phone: +49 (0) 8709 9229-664 E-Mail: csimmet@minitube.de Internet: www.minitube.de Fallstrasse 9 D-81369 München Phone: +49 (0) 160 777 0880 E-Mail: info@mk2.bio Internet: www.mk2.bio Max-Lebsche-Platz 31 D-81377 München Phone: +49 (0) 89 990 17-0 E-Mail: info@mll.com Internet: www.mll.com Breslauer Strasse 2 D-85386 Eching Phone: +49 (0) 89 319 048 40 E-Mail: info@molecular-machines.com Internet: www.molecular-machines.com 103

MSD SHARP & DOHME GMBH PHARMA & CHEMICAL INDUSTRY Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD‘s core business is the discovery, development, production and distribution of pre- scription medicines, vaccines, biologic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dol- lars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich. Twitter: @MSD_Deutschland multi service monitoring CRO Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development, multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and “DIN ISO 14155”. multimmune GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Imaging, Antibody, Oncology, Immune Therapy, Drug Development, Personalized Medicine, Cell Therapy multimmune GmbH is a clinical stage biopharmaceutical company delivering new theranostics for tumours expressing surface-bound Hsp70, a tumor-spe- cific marker which is present on about 70% of all cancer entities. Current pipelines include: activated autologous Natural Killer (NK) cells (Phase II for lung cancer), monoclonal antibody-based therapeutics and imaging (preclin- ical) and inducing tumor-specific apoptosis using recombinant human serine protease (preclinical). 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Lindenplatz 1 D-85540 Haar Phone: +49 (0) 800 673 673 673 E-Mail: infocenter@msd.de Internet: www.msd.de Maxhüttenstraße 11 D-93055 Regensburg Phone: +49 (0) 941 3782498 E-Mail: info@multi-service-monitoring.de Internet: www.multi-service-monitoring.de Kirchenstrasse 82 D-81675 München E-Mail: graham.pockley@multimmune.com Internet: www.multimmune.com 105

nanoSaar AG NANOTECHNOLOGY Keywords: Nanobiotechnology THE POWER OF NANO! nanoSaar AG is a leading provider of tailor-made nanotechnology solutions that give a wide range of partners from the chemi- cal industry a competitive advantage. - Very homogeneous, superior product quality - Continuous, cost-effective production process - Fast, simple scale- up for industrial chemical production - Business opportunities with license or joint venture models - You can find out more at: www.nanosaar.com NanoTemper Technologies GmbH BIOTECH DEVICES & REAGENTS Keywords: Automation, Vaccines, Bioprocessing, Drug Development, Bioanalytics, Device NanoTemper is a global leader for optical measurements in R&D and bio- manufacturing. NanoTemper has a strong customer focus and stands for strong commitment to quality, ease of use and high precision instrumenta- tion. The globally operating team of experts strongly focuses on the user’s benefits by ensuring maximum efficiency for the Pharmaceutical and Biotech industries as well as academic research. With our MST, TRIC & nanoDSF technologies, we provide knowledge about the most difficult targets. NDA Regulatory Service GmbH CRO Keywords: Pharmacovigiliance, Drug Development, Medical Writing, R&D Service, Regulatory Affairs NDA is a leading regulatory consultancy, supporting drug development com- panies of all sizes on the shortest and most economic path to approval and patient access. Our experienced team of 150 consultants (30 in Munich) pro- vide advice on all phases of development and therapeutic areas, including procedure and submission management, for both US and EU. Our specialist Advisory Board, consisting of very senior ex-regulators, provides indepen- dent strategic advice with an inside the agencies view. Neaspec GmbH BIOTECH DEVICES & REAGENTS Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institu- tions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Würmstraße 4 D-82319 Starnberg Phone: +49 (0) 8151 959022-0 E-Mail: info@nanosaar.com Internet: www.nanosaar.com Flößergasse 4 D-81369 München Phone: +49 (0) 89 4522 895-0 E-Mail: info@nanotemper.de Internet: www.nanotempertech.com Neumarkter Straße 18 D-81673 München Phone: +49 (0) 89 3585-4000 E-Mail: munich@ndareg.com Internet: www.ndareg.com Eglfinger Weg 2 D-85540 Haar (Munich) Phone: +49 (0) 89 420 797 203 -30 E-Mail: info@neaspec.com Internet: www.neaspec.com 107

Novartis Pharma GmbH PHARMA Novartis is reimagining medicines to help improve and extend people’s lives. We use innovation and digital technologies to develop therapies in areas with high unmet medical need. We invest a high share of our turnover in research and development. Our products reach around 800 million people worldwide and we strive to expand access to them. In Germany Novartis employs around 7,400 people at 12 locations and around 109,000 worldwide. www.novartis.de and www.novartis.com numares AG BIOTECH THERAPEUTICS & DIAGNOSTICS Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases numares AG, based in Regensburg develops and markets innovative diag- nostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON® NMR system. We have a successful commercial base especially in laboratories in the USA. Nuvisan GmbH CRO Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market. Octamer GmbH BIOTECH THERAPEUTICS & DIAGNOSTICS Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcrip- tional regulation. We research nucleosomes for decades and offer the unique opportunity to provide disease-relevant substrates to epigenetic tar- gets - both for academic research and drug discovery. 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Roonstr. 25 D-90429 Nürnberg Phone: +49 (0) 911 273-0 E-Mail: angelika.gaufer@novartis.com Internet: www.novartis.de Am BioPark 9 D-93053 Regensburg Phone: +49 (0) 941 280949-00 E-Mail: jobs@numares.com Internet: www.numares.com Wegenerstr. 13 D-89231 Neu-Ulm Phone: +49 (0) 731 9840-0 E-Mail: bdinfo@nuvisan.com Internet: www.nuvisan.com Friedemann-Bach-Str. 95 D-82166 Gräfelfing Phone: +49 (0) 89 21538575 E-Mail: support@octamer.com Internet: www.octamer.de 109